Engene announces board and leadership appointments to support commercial readiness

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn or “engene” or the “company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its board of directors: philip astley-sparke, william grossman, m.d., ph.d., and michael heffernan, r.ph. their combined experience across gene therapy, oncology, clinical development, and global product launches will support engene's strategic transition toward planned commerci.
ENGN Ratings Summary
ENGN Quant Ranking